Revelation Biosciences Inc (REVB)

Mar 17, 2025, 6:00 AM EDT - 17 days ago

Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells

Mar 13, 2025, 6:00 AM EDT - 21 days ago

Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference

Mar 6, 2025, 4:15 PM EST - 4 weeks ago

Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024

Feb 26, 2025, 6:00 AM EST - 5 weeks ago

Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients

Feb 24, 2025, 6:00 AM EST - 5 weeks ago

Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval

Jan 24, 2025, 6:00 AM EST - 2 months ago

Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025

Jan 21, 2025, 6:00 AM EST - 2 months ago

Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients

Jan 13, 2025, 6:00 AM EST - 2 months ago

Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025

Jan 6, 2025, 6:00 AM EST - 3 months ago

Nasdaq Grants Revelation Biosciences Inc. Continued Listing

Dec 3, 2024, 8:38 AM EST - 4 months ago

Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds

Dec 2, 2024, 6:00 AM EST - 4 months ago

Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND

Nov 12, 2024, 6:00 AM EST - 5 months ago

Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply

Nov 8, 2024, 4:15 PM EST - 5 months ago

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024

Sep 24, 2024, 6:00 AM EDT - 6 months ago

Revelation Biosciences' Gemini Induces Dose Dependent Significant Increases in IL-10

Aug 21, 2024, 5:30 PM EDT - 8 months ago

Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds

Aug 9, 2024, 4:15 PM EDT - 8 months ago

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024

Jun 24, 2024, 9:00 AM EDT - 10 months ago

Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity

Jun 13, 2024, 9:21 AM EDT - 10 months ago

Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini

May 10, 2024, 4:52 PM EDT - 11 months ago

Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024

Mar 22, 2024, 4:15 PM EDT - 1 year ago

Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023

Mar 13, 2024, 9:00 AM EDT - 1 year ago

Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)

Mar 12, 2024, 9:00 AM EDT - 1 year ago

Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference

Mar 4, 2024, 9:00 AM EST - 1 year ago

Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini

Feb 13, 2024, 9:00 AM EST - 1 year ago

Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)

Feb 9, 2024, 8:35 AM EST - 1 year ago

Top 5 Health Care Stocks That Are Preparing To Pump In February

CNSP GILD ZLAB

Feb 5, 2024, 4:41 PM EST - 1 year ago

Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering

Feb 1, 2024, 6:00 AM EST - 1 year ago

Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering

Jan 30, 2024, 9:00 AM EST - 1 year ago

Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)

Jan 23, 2024, 9:00 AM EST - 1 year ago

Revelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split Effective January 25, 2024

Nov 13, 2023, 4:05 PM EST - 1 year ago

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023

Oct 12, 2023, 9:00 AM EDT - 1 year ago

Gemini Induces Pharmacologic Activity and Related Physiologic Changes in Multiple Preclinical Studies

Oct 4, 2023, 9:00 AM EDT - 1 year ago

Revelation Biosciences, Inc. to Present at the 2023 ROTH Healthcare Opportunities Conference

Oct 2, 2023, 9:00 AM EDT - 1 year ago

Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors

Aug 11, 2023, 4:10 PM EDT - 1 year ago

Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2023

Jun 29, 2023, 9:00 AM EDT - 1 year ago

REMINDER: Revelation Biosciences, Inc. Urges All Stockholders to Vote at the 2023 Annual Meeting of Stockholders

Jun 12, 2023, 4:15 PM EDT - 1 year ago

Revelation Biosciences Inc. Announces Adjournment of 2023 Annual Meeting of Stockholders to July 7, 2023 and Additional Proposal

May 22, 2023, 9:00 AM EDT - 2 years ago

Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2023 and Recent Corporate Progress

Mar 30, 2023, 5:42 PM EDT - 2 years ago

Revelation Biosciences Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Recent Corporate Progress

Mar 13, 2023, 9:00 AM EDT - 2 years ago

Revelation Biosciences Inc. Appoints Dr. Julia Bohannon and Dr. Antonio Hernandez to Scientific Advisory Board

Mar 6, 2023, 9:00 AM EST - 2 years ago

Revelation Biosciences Inc. to Participate in a Fireside Chat at the 35th Annual Roth Conference

Feb 13, 2023, 4:20 PM EST - 2 years ago

Revelation Biosciences Inc. Announces Closing of $15.6 Million Public Offering

Feb 9, 2023, 9:42 AM EST - 2 years ago

Revelation Biosciences Inc. Announces Pricing of $15.6 Million Public Offering

Feb 7, 2023, 9:00 AM EST - 2 years ago

Revelation Biosciences Inc. Announces Preclinical Biomarker Data Supporting Activity of REVTx-300

Jan 31, 2023, 12:00 PM EST - 2 years ago

Revelation Biosciences Inc. Announces 1-for-35 Reverse Stock Split effective February 1, 2023 and Results of Special Meeting of Stockholders

Jan 10, 2023, 9:00 AM EST - 2 years ago

Revelation Biosciences Inc. Announces Mandatory Unit Separation to Occur on January 13, 2023

Nov 18, 2022, 9:00 AM EST - 2 years ago

Revelation Biosciences Inc. Announces Future Clinical Development Plans Based on Recent Biomarker Analysis and Significant Reduction in New Collagen Deposition (Fibrosis) in Preclinical Model

Nov 10, 2022, 4:30 PM EST - 2 years ago

Revelation Biosciences Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2022 and Recent Corporate Progress

Oct 25, 2022, 11:13 AM EDT - 2 years ago

Revelation Biosciences Inc. Announces Positive Results in Preclinical Model of Acute and Chronic Kidney Disease

Oct 6, 2022, 7:00 AM EDT - 2 years ago

Revelation Biosciences Inc. and Vanderbilt University Enter Exclusive Worldwide License Agreement

Aug 15, 2022, 5:30 PM EDT - 2 years ago

Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Recent Corporate Progress